AzTrials
AzTrials

Anxiety, PreoperativeNCT06670846

Management of Preoperative Anxiety in Children: Could a Lollipop Be the Solution?

A study testing Lollipop and distraction using intranasal Midazolam in people with Anxiety, Preoperative, run by Tunis University at 1 site in Tunisia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the study is to evaluate the effectiveness of distraction using a lollipop versus premedication with intranasal midazolam to manage preoperative anxiety in pediatric anesthesia. Read more about this study

Who is it for?
Ages 4 to 10 yearsHealthy volunteers can take part
Conditions the study is for
Anxiety, Preoperative
What is being tested?
Lollipop and distraction using intranasal Midazolam
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
63 participants
Where
1 siteTunisia
Study dates
2 Jan 2024to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 10 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Age > 4 ans , ASA 1 ou 2

Who cannot join

  • Children who rejected premedication - The occurrence of perioperative complications

Trial locations and contacts

1 site in 1 country.

salma Aouadi, consultant contact

0021656652210

salmaaouadi1@gmail.com

Tunisia1 site, 1 recruiting
  • Bechir Hamza hospital

    Tunis, Tunis Governorate, 2001

    salma Aouadi, consultant, 56652210, salmaaouadi1@gmail.com

    Salma Aouadi, consultant

    Recruiting

Other trials in Tunisia

About this study

The aim of the study is to evaluate the effectiveness of distraction using a lollipop versus premedication with intranasal midazolam to manage preoperative anxiety in pediatric anesthesia.

Read the detailed description

Participants were randomized into two groups to receive either intranasal midazolam at 0.3 mg/kg (group M) or distraction using a lollipop (group L) 15 minutes before entering the operating room. The anesthetic technique was standardized: a peripheral intravenous line, intravenous induction (propofol and fentanyl), airway management with an age-appropriate IGEL mask, and maintenance with sevoflurane. Anxiety was assessed using the modified Yale Preoperative Anxiety Scale (mYPAS) before and after premedication. The investigators also evaluate the level of sedation upon entering the operating room, the quality of parent separation, acceptance of the facemask during induction, and emergence of agitation using the Pediatric Anesthesia Emergence Delirium Scale (PAEDS).

Being tested
Lollipop, distraction using intranasal Midazolam
Keywords
anxiety, children, anesthesia, distraction, midazolam
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LollipopDevice

    Distraction using a Lollipop 15 minutes before anesthesia

  • distraction using intranasal MidazolamDrug

    Distraction using intranasal Midazolam 15 minutes before anesthesia

Study groups in NCT06670846
Study groupRoleWhat they receive
Lollipop armExperimentalDistraction using a lollipop (group L) 15 minutes before entering the operating room
Receives: Device: Lollipop
Midazolam armActive comparatorIntranasal midazolam at 0.3 mg/kg 15 minutes before anesthesia
Receives: Drug: distraction using intranasal Midazolam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. anxiety

    Anxiety was assessed using the modified Yale Preoperative Anxiety Scale (mYPAS) before and after premedication. The myPAS score includes 5 items, with a minimum value of 4 and a maximum value of 22; a higher score indicates a major anxiety.

    Measured: immediatly before premedication and 15 minutes after premedication

Secondary outcomes (2)
  1. agitation

    Emergence agitation assessed using the Pediatric Anesthesia Emergence Delirium Scale (PAEDS), which has a minimum score of 0 and a maximum score of 20. A higher score indicates more severe agitation during emergence from anesthesia.

    Measured: 10 minutes after extubation

  2. parent separation

    The quality of parent separation Defined by 3 items: the child waits near their parents rated as 1, clings to their parents rated as 2, or refuses separation rated as 3

    Measured: 15 minutes after premedication

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2024
  2. Study start2 Jan 2024
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Chidren were randomized into two groups to receive either intranasal midazolam at 0.3 mg/kg (group M) or distraction using a lollipop (group L) 15 minutes before entering the operating room
Masking
None (open label)
Enrolment
63 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06670846
Sponsor's protocol ID
302023
Status last verified
Oct 2024
First submitted
21 Oct 2024
Last updated
1 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Lollipop and distraction using intranasal Midazolam in people with Anxiety, Preoperative, run by Tunis University at 1 site in Tunisia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact salma Aouadi, consultant (0021656652210, salmaaouadi1@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

anxiety (time frame: immediatly before premedication and 15 minutes after premedication). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in